Tiratricol, Matching placebo (for participants allocated to the placebo group in the Randomized Treatment Period)
MCT8-2021-3
Phase 3 small_molecule active
Quick answer
Tiratricol, Matching placebo (for participants allocated to the placebo group in the Randomized Treatment Period) for Monocarboxylate Transporter 8 (MCT8) deficiency is a Phase 3 program (small_molecule) at Rare Thyroid Therapeutics International AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Rare Thyroid Therapeutics International AB
- Indication
- Monocarboxylate Transporter 8 (MCT8) deficiency
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active